Effect of Interleukin-1 receptor antagonist on insulin sensitivity in obese, insulin resistant individuals

Completed

• Conditions: 10018424; maturity-onset diabetes; type 2 diabetes mellitus

• Registration Number: NL-OMON33714
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

body mass index > 30 kg/m2
3 or more characteristics of the metabolic syndrome

Exclusion Criteria

elevated risk for infections
pregnancy or breast-feeding
liver or renal disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>insulin sensitivity after 4 weeks treatment with anakinra compared with<br /><br>placebo.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>pancreatic beta-cell function<br /><br>fat cell morfology<br /><br>Insulin sensitivity of fat cells<br /><br>glucose control (fasting glucose, HbA1c)<br /><br>concentration of hormonal (leptin, adiponectin, insulin, glucagon) and<br /><br>inflammatory factors (Interleukin 1, 6, 18, hsCRP) and lipid profile</p><br>